Badania AIPRI i ACCOMPLISH. Czy dysponujemy metodami skutecznej kardionefroprotekcji? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2011
Słowa kluczowe:
nadciśnienie tętnicze, subkliniczne powikłania narządowe, benazepril
##plugins.themes.bootstrap3.article.main##
Abstrakt
W postępowaniu leczniczym mającym na celu ochronę narządową i poprawę rokowania w nadciśnieniu tętniczym ważną rolę odgrywa hamowanie aktywności układu renina-angiotensyna-aldosteron. W badaniu AIPRI udowodniono, że stosowanie benazeprilu w populacji pacjentów z nefropatią niecukrzycową pozwala w znaczący sposób zmniejszyć ryzyko wystąpienia schyłkowej niewydolności nerek i konieczności leczenia nerkozastępczego. Również w badaniu ACCOMPLISH dowiedziono, że stosowanie benazeprilu w skojarzonej terapii nadciśnienia tętniczego wiąże się z istotną redukcją ryzyka sercowo-naczyniowego oraz skuteczną prewencją niewydolności nerek.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grabysa , R. (2011). Badania AIPRI i ACCOMPLISH. Czy dysponujemy metodami skutecznej kardionefroprotekcji? . Medycyna Faktów , 4(2(11), 59-65. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2536
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mathers C., Stevens G., Mascarenas M.: Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization, 2009 [online].
2. MacMahon S., Peto R., Butler J. et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. Kannel W.B.: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275(20): 1571-1576.
4. Klag M.J., Whelton P.K., Randall B.L. et al.: Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334: 13-18.
5. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
6. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
7. Stevens L.A., Coresh J., Greene T., Levey A.S.: Assessing kidney function – measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006; 354: 2473-2483.
8. Foley R.N., Parfrey P.S., Sarnak M.J.: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Am. J. Kidney Dis. 1998; 32(suppl 3): S112-S119.
9. Król E., Rukowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
10. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
11. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
12. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
13. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
14. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005; 99:S57-S65.
15. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
16. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D.: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
17. Kronenberg F., Kuen E., Ritz E. et al.: Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 2000; 11: 105-115.
18. Fliser D., Pacini G., Engelleiter R. et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998; 53: 1343-1347.
19. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
20. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
21. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Bakris G.L., Serafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375: 1173-1181.
2. MacMahon S., Peto R., Butler J. et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. Kannel W.B.: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275(20): 1571-1576.
4. Klag M.J., Whelton P.K., Randall B.L. et al.: Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334: 13-18.
5. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
6. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
7. Stevens L.A., Coresh J., Greene T., Levey A.S.: Assessing kidney function – measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006; 354: 2473-2483.
8. Foley R.N., Parfrey P.S., Sarnak M.J.: Clinical epidemiology of cardiovascular disease in chronic kidney disease. Am. J. Kidney Dis. 1998; 32(suppl 3): S112-S119.
9. Król E., Rukowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
10. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
11. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
12. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
13. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
14. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005; 99:S57-S65.
15. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
16. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D.: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
17. Kronenberg F., Kuen E., Ritz E. et al.: Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 2000; 11: 105-115.
18. Fliser D., Pacini G., Engelleiter R. et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998; 53: 1343-1347.
19. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
20. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
21. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Bakris G.L., Serafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375: 1173-1181.